Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Pha…
Biotechnology
US, Waltham [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
Xilio Therapeutics, Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDXilio Therapeutics, Inc. can't present revenue by segment